Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema

Key Takeaways IONS shares rose 2.5% after the European Commission approved Dawnzera to prevent recurrent HAE attacks.Ionis partnered with Otsuka ex-U.S., & is eligible for a $15M milestone payment with approval in the EU.Dawnzera cut mean monthly HAE attacks by 94% at one year in the OASISplus study.Ionis (IONS) and its Japanese partner, Otsuka Pharmaceutical, announced that the European Commission has approved Dawnzera (donidalorsen) for the prevention of recurrent attacks of hereditary angioedema (HAE) in ...